INS and Hyperglycemia: A large multicenter RCT on the role of basal insulin therapy versus standard of care in PTDM prevention in patients with post-transplant hyperglycemia did not find a significant difference in incidence of PTDM at 12 months in both groups (12.2% vs 14.7%); however, after per-protocol analysis was adjusted for polycystic kidney disease and glomerular nephritis, a significant difference at one-year endpoint (PTDM) development was observed [26].